BioPharma

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs...

There is no shred of doubt that artificial intelligence in genomics is indeed reshaping the healthcare spectrum, offering unmatched opportunities to decode the intricacies of the human genome. Apparently, in 2024, the global artificial intelligence and genomics market was valued...

Because of new ideas, concerns about safety for consumers, and government rules, the pharmaceutical business is about to enter a new era in packing. As we are passing through 2025, several significant trends are emerging that are reshaping pharmaceutical...

Selecting the appropriate contract research and manufacturing option is crucial for biopharmaceutical companies starting new initiatives related to the creation of novel antibodies. Biopharma companies are seeking reliable CDMO partnerships for specialized capacity and assistance due to the industry's growing...

The biopharmaceutical sector is driven by rising global healthcare needs, technology, technological advancements, and the imperative to remain agile in a highly regulated environment. The need for increased efficiency, cost savings, and compressed timelines has resulted in the leading...

A New Era of Biopharma Production with AI The biopharma industry is undergoing a transformation as it capitalises on the potential of artificial intelligence (AI) to revolutionise production processes.  Manufacturers are currently facing the most significant challenge in history: the...

The biopharmaceutical industry in the Asia-Pacific area has seen a significant strategic shift in recent years; this trend is now commonly acknowledged as Asia's bio sovereignty movement. Countries like China, India, Japan, South Korea, and Singapore are making daring...